Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010033/S053

QuantiFERON-TB Gold Plus Test

Qiagen · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONP010033/S053

What did the FDA decide?

The FDA posted a 30-Day Notice for PMA supplement P010033/S053, dated October 14, 2026, from applicant Qiagen. The decision field is OK30, and the supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The stated change is to the lyophilization process for the QuantiFERON-TB Gold Plus Test, a cell-mediated immunity test for Mycobacterium tuberculosis under product code NCD.

This supplement is not a new approval of the whole system and does not establish a new indication or clinical effectiveness finding. The source statement reports only the process-change scope; it does not include attached FDA summary documents or further technical detail on what specifically changed within lyophilization. The relationship to the original PMA is limited to the identifier P010033, and no present-day labeling or clinical use can be inferred from this record.

FDA approval order statement

changes to the lyophilization process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Oct 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010033/S053
Regulatory pathway
PMA supplement
Applicant
Qiagen
Product code
NCD
Decision code
OK30
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.

Applicant
Qiagen
Product code
NCD
FDA device class
3

For the original device and its historical approval scope, see PMA P010033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010033 · Original PMA

    QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE

  2. P010033/S053 received

    Application receipt date recorded by FDA.

  3. P010033/S053 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010033

Product / regulatory recordCompanyPathwayDecision dateSource
QiagenPMA approvalNov 28, 2001FDA

Explore the linked device profile

Other records with product code NCD

Product / regulatory recordCompanyPathwayDecision dateSource
DiaSorin, Inc.PMA supplementSep 24, 2026FDA
DiaSorin, Inc.PMA approvalNov 26, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Qiagen

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
19300 Germantown Rd., Germantown, MD, 20874

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records